Please assess the completion status of the following clinical trial:

Trial Title: ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Existence of one or more metastases of of colorectal cancer (CRC) expressing the CEA , potentially accessible by surgical or thermo resection at the moment of the diagnosis or at relapse.~OR~* Isolated and progressive elevation of plasma CEA during the monitoring of CRC with high metastatic risk~* More than 18 years~* Negative pregnancy test for women of childbearing age. Women of childbearing age should take effective continuous contraception for 3 months.~* At least 4 weeks after the last treatment and after recovery of potential toxicity~* Karnofsky more than 70 or ECOG 0-1~* Life expectancy of at least 6 months~* CEA positive immunohistochemistry or plasma CEA supperior or equal to the normal level~* Creatinin less or equal 200 micromol/L~* Signed informed consent~* geographical proximity~Exclusion Criteria:~* Pregnancy or breastfeeding~* Serious illness or comorbidity assessed risk~* History of other cancer within 5 years, with the exception of skin carcinomas other than melanomas or in-situ carcinoma of the cervix~* Anti-antibody presence in patients who have already received antibody~* Hypersensitivity to antibodies or proteins~* Intellectual inability to sign the informed consent~* Insulin-dependent diabetic patient or non-insulin dependent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TF2 antibody/68Ga-IMP-288 (Type: EXPERIMENTAL): TF2 antibody/68Ga-IMP-288

Based on this trial design, predict the completion outcome and termination type (if applicable).